臨床検査54巻11号

2010年10月発行

特集 新時代のワクチン戦略について考える 各論 3. 期待されているこれからのワクチン

3) HIV

著者： 松岡佐織¹ 俣野哲朗¹

所属機関： ¹東京大学医科学研究所感染症国際研究センター

ページ範囲：P.1407 - P.1412

HIVが発見されて以来，HIVの感染拡大の防止に向け多くの試みがなされてきたが，今なお有効な予防ワクチンの実用化には至っていない．本稿ではこれまでのHIV感染症克服に向けた取り組みの歴史を振り返りながら，今ひとたび予防HIVワクチン開発の必要性およびその展望を考えたい．

参考文献

1) Goulder PJ, Watkins DI:HIV and SIV escape:implications for vaccine design. Nat Rev Immunol　4：630-640，2004

2) Goulder PJ, Watkins DI:Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol　8：619-630，2008

3) Trachtenberg E, Korber B, Sollars C, et al:Advantage of rare HLA supertype in HIV disease progression. Nat Med　9：928-935，2003

4) WHO, UNICEF, UNAIDS:Toward universal access, Progress Report. Geneva and Paris, (http://www.who.int/hiv/pub/2009progressreport/en/index.html), 2009

5) O´ Gorman DA, Nyirenda LJ, Thebald SJ:prevention of mother-to-child transmission of HIV infection:views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi. BMC Public Health　10：354，2010

6) When to Start Consortium, Sterne JA, May M, et al:Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients:a collaborative analysis of 18 HIV cohort studies. Lancet　373：1352-1363，2009

7) Kovacs JA, Lempicki RA, Sidorov IA, et al:Induction of prolonged survival of CD4＋ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest　115：2139-2148，2005

8) INSIGHT-ESPRIT Study Group, SILCAAT Scientific Committee, Abrams D, et al:Interleukin-2 therapy in patients with HIV infection. N Engl J Med　361：1548-1559，2009

9) Di Mascio M, Sereti I, Matthews LT, et al:Nave T-cell dynamics in human immunodeficiency virus type 1 infection:effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol　80：2665-2674，2006

10) Mattapallil JJ, Douek DC, Hill B, et al:Massive infection and loss of memory CD4＋ T cells in multiple tissues during acute SIV infection. Nature　434：1093-1097，2005

11) Yamamoto H, Kawada M, Takeda A, et al:Post-infection immunodeficiency virus control by neutralizing antibodies. PLoS One　2：e540，2007

12) Kiepiela P, Ngumbela K, Thobakgale C, et al:CD8＋ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med　13：46-53，2006

13) Tsukamoto T, Takeda A, Yamamoto T, et al:Impact of cytotoxic-T-lymphocyte memory induction without virus-specific CD4＋ T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. J Virol　83：9339-9346，2009

14) Yamamoto T, Iwamoto N, Yamamoto H, et al:Polyfunctional CD4＋ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection. J Virol　83：5514-5524，2009

15) Buchbinder SP, Mehrotra DV, Duerr A, et al:Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study):a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet　372：1881-1893，2008

16) McElrath MJ, De Rosa SC, Moodie Z, et al:HIV-1 vaccine-induced immunity in the test-of concept Step Study:a case-cohort analysis. Lancet　372：1894-1905，2008

17) Hutnick NA, Carnathan DG, Dubey SA, et al:Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4＋ T cells. Nat Med　15：876-878，2009

18) O'Brien KL, Liu J, King SL, et al:Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med　15：873-875，2009

19) Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al:Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis　188：219-227，2003

20) Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al:Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med　361：2209-2220，2009